Skip to main content
Erschienen in: Osteoporosis International 10/2017

15.06.2017 | Short Communication

The cost of a patient activation intervention for achieving successful outcomes: results from the PAADRN randomized controlled trial

verfasst von: F. D. Wolinsky, S. F. Hall, Y. Lou, S. W. Edmonds, K. G. Saag, D. W. Roblin, N. C. Wright, M. P. Jones, P. Cram, J. R. Curtis, S. L. Morgan, J. A. Schlechte, J. H. Williams, D. J. Zelman, on behalf of the PAADRN Investigators

Erschienen in: Osteoporosis International | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Summary

In a large, pragmatic clinical trial, we calculated the costs of achieving four successful patient-centered outcomes using a tailored patient activation DXA result letter accompanied by a bone health brochure. The cost to achieve one successful outcome (e.g., a 0.5 standard deviation improvement in care satisfaction) ranged from $127.41 to $222.75.

Introduction

Pragmatic randomized controlled trials (RCTs) should focus on patient-centered outcomes and report the costs for achieving those outcomes. We calculated per person incremental intervention costs, the number-needed-to-treat (NNT), and incremental per patient costs (cost per NNT) for four patient-centered outcomes in a direct-to-patient bone healthcare intervention.

Methods

The Patient Activation after DXA Result Notification (PAADRN) pragmatic RCT enrolled 7749 patients presenting for DXA at three health centers between February 2012 and August 2014. Interviews occurred at baseline and 52 weeks post-DXA. Intervention subjects received an individually tailored DXA result letter accompanied by an educational bone health brochure 4 weeks post-DXA, while the usual care subjects did not. Outcomes focused on patients (a) correctly identifying their results, (b) contacting their providers, (c) discussing their results with their providers, and (d) satisfaction with their bone healthcare. NNTs were determined using intention-to-treat linear probability models, per person incremental intervention costs were calculated, and costs per NNT were computed.

Results

Mean age was 66.6 years old, 83.8% were women, and 75.3% were non-Hispanic whites. The incremental per patient cost (costs per NNT) to increase the ability of a patient to (a) correctly identify their DXA result was $171.07; (b) contact their provider about their DXA result was $222.75; (c) discuss their DXA result with their provider was $193.55; and (d) achieve a 0.5 SD improvement in satisfaction with their bone healthcare was $127.41.

Conclusion

An individually tailored DXA result letter accompanied by an educational brochure can improve four patient-centered outcomes at a modest cost.

Trial registration

clinicaltrials.​gov identifier NCT01507662
Literatur
1.
Zurück zum Zitat Schwartz D, Lellouch J (1967) Explanatoy and pragmatic attitudes in therapeutic trials. J Chron Dis 20:637–648CrossRefPubMed Schwartz D, Lellouch J (1967) Explanatoy and pragmatic attitudes in therapeutic trials. J Chron Dis 20:637–648CrossRefPubMed
2.
Zurück zum Zitat Sox HC, Lewis RJ (2016) Pragmatic trials: practical answers to “real world” questions. JAMA 316:1205–1206CrossRefPubMed Sox HC, Lewis RJ (2016) Pragmatic trials: practical answers to “real world” questions. JAMA 316:1205–1206CrossRefPubMed
3.
Zurück zum Zitat Ford I, Norrie J (2016) Pragmatic Trials N Engl J Med 375: 454–463. doi: 10.1056/NEJMra1510059 Ford I, Norrie J (2016) Pragmatic Trials N Engl J Med 375: 454–463. doi: 10.1056/NEJMra1510059
5.
8.
9.
Zurück zum Zitat Burge R, Dawson-Hughes B, Solomon D et al (2014) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475. doi:10.1359/jbmr.061113 CrossRef Burge R, Dawson-Hughes B, Solomon D et al (2014) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22:465–475. doi:10.​1359/​jbmr.​061113 CrossRef
13.
Zurück zum Zitat Cram P, Wolinsky FD, Lou Y et al (2016) Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial. Osteoporos Int 27:3513–3524. doi:10.1007/s00198-016-3681-9 CrossRefPubMed Cram P, Wolinsky FD, Lou Y et al (2016) Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial. Osteoporos Int 27:3513–3524. doi:10.​1007/​s00198-016-3681-9 CrossRefPubMed
17.
Zurück zum Zitat Cram P, Schlechte J, Christensen A (2006) A randomized trial to assess the impact of direct reporting of DXA scan results to patients on quality of osteoporosis care. J Clin Densitom 9:393–398CrossRefPubMed Cram P, Schlechte J, Christensen A (2006) A randomized trial to assess the impact of direct reporting of DXA scan results to patients on quality of osteoporosis care. J Clin Densitom 9:393–398CrossRefPubMed
18.
Zurück zum Zitat Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733CrossRefPubMed Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733CrossRefPubMed
19.
Zurück zum Zitat Sanders GD, Neumann PJ, Basu A et al (2016) Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 316:1093–1103. doi:10.1001/jama.2016.12195 CrossRefPubMed Sanders GD, Neumann PJ, Basu A et al (2016) Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 316:1093–1103. doi:10.​1001/​jama.​2016.​12195 CrossRefPubMed
20.
Zurück zum Zitat Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG (2017) Cost-effectiveness in health and medicine, 2nd edn. Oxford University Press, New York Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG (2017) Cost-effectiveness in health and medicine, 2nd edn. Oxford University Press, New York
Metadaten
Titel
The cost of a patient activation intervention for achieving successful outcomes: results from the PAADRN randomized controlled trial
verfasst von
F. D. Wolinsky
S. F. Hall
Y. Lou
S. W. Edmonds
K. G. Saag
D. W. Roblin
N. C. Wright
M. P. Jones
P. Cram
J. R. Curtis
S. L. Morgan
J. A. Schlechte
J. H. Williams
D. J. Zelman
on behalf of the PAADRN Investigators
Publikationsdatum
15.06.2017
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 10/2017
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-017-4113-1

Weitere Artikel der Ausgabe 10/2017

Osteoporosis International 10/2017 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.